Find A Physician

Return to Treatment of Multiple Myeloma Overview

More on Treatment of Multiple Myeloma

Hospital News

Return to Treatment of Multiple Myeloma Overview

More on Treatment of Multiple Myeloma

Research and Clinical Trials

Return to Treatment of Multiple Myeloma Overview

More on Treatment of Multiple Myeloma

Clinical Services

Return to Treatment of Multiple Myeloma Overview

More on Treatment of Multiple Myeloma

Weill Cornell Cancer Center

Treatment of Multiple Myeloma

Chemotherapy is the primary treatment for hematologic cancers, though some patients may receive radiation therapy as well and/or a transplant of stem cells or bone marrow.

Multiple myeloma is most commonly treated with chemotherapy. Patients may receive a combination of treatments, depending on the type and stage of their disease. Examples of treatment approaches include:

  • Anticancer drugs: thalidomide, cyclophosphamide, vincristine, doxorubicin melphalan, bortezomib, and/or lenalidomide
  • Steroid drugs such as dexamethasone and prednisone are often given in combination with chemotherapy
  • High doses of chemotherapy with a stem cell transplant (in which some of a patient's blood-forming cells are removed before chemotherapy and returned afterward to help the patient's immune system re-establish itself)
  • Radiation therapy
  • Interferon after chemotherapy to maintain remission

The Center of Excellence for Lymphoma and Myeloma at Weill Cornell has become one of the nation's largest centers dedicated to providing superior care for patients with myeloma.

  • Patients are referred to us primarily by physicians in the tri-state area. We receive referrals nationally as well.
  • Our clinical research program is translational in nature, bringing laboratory discoveries to the clinic with the support of grants from the National Cancer Institute, the Multiple Myeloma Research Foundation, and the Leukemia & Lymphoma Society.
  • We refer between 60 and 70 patients with myeloma each year to Weill Cornell's stem cell transplant program.
  • Our physicians are recognized as authorities in the field and have served as principal investigators to establish international guidelines guiding the management of myeloma.

Clinical Trials

Weill Cornell has been at the forefront of drug development for myeloma and is establishing a comprehensive program focused on targeted therapies for patients with disease of any stage.

  • We conducted key clinical trials of the BiRD regimen (composed of the drugs Biaxin, Revlimid, and dexamethasone), which led to its use and acceptance as initial therapy for myeloma.
  • We have been among the leading centers enrolling patients in clinical trials of drugs such as bortezomib, lenalidomide, oblimersen, and carfilzomib.

Find a multiple myeloma clinical trial at the Weill Cornell Cancer Center.

  • Bookmark
  • Print

    Find a Doctor

Click the button above or call
1 877 NYP WELL


eNewsletters
Top of page